Drug Profile

BRL 302

Alternative Names: BRL-302; PSMA-UCAR T

Latest Information Update: 01 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BRL Medicine
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

01 Mar 2025 BRL Medicine plans a phase I trial for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in China (NCT06895811)
09 Oct 2024 BRL Medicine plans a phase-I trial for Neuromyelitis optica in November 2024 (Parenteral), (NCT06633042)
15 Jul 2022 Preclinical trials in Multiple myeloma in China (Parenteral) before July 2022 (BRL Medicine pipeline, July 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com